Klivira
Request demo

Streamlining Humana Beovu Prior Authorization for Wet AMD

Navigating the complexities of **Humana Beovu prior authorization** is a critical operational task for ophthalmology and retina practices.

For revenue cycle directors and prior authorization coordinators, securing timely approvals for high-cost specialty medications like Beovu is essential for patient care and financial health. Understanding Humana's specific requirements, submission channels, and policy nuances can significantly impact approval rates and administrative burden.

Understanding Beovu for Wet AMD Treatment

Beovu (brolucizumab) is an anti-VEGF (vascular endothelial growth factor) inhibitor prescribed for neovascular (wet) age-related macular degeneration (AMD), a leading cause of vision loss. As an intravitreal injection, its administration typically falls under the medical benefit, making prior authorization a frequent requirement across commercial and Medicare Advantage plans, including Humana.

Humana's Prior Authorization Channels for Medical Benefit Drugs

Humana primarily directs medical prior authorization submissions, including those for Beovu, through its integration with Availity Essentials. Providers can initiate PA requests, check eligibility, and upload supporting clinical documentation via the Availity portal. For systems with established integrations, X12 278 transactions are also supported via clearinghouses for medical benefit PA.

Humana Utilization Management Policies and Criteria for Beovu

Humana publishes medical policies and coverage determinations on its provider site, which outline the medical necessity criteria for drugs like Beovu. For Medicare Advantage members, these policies must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), ensuring that criteria are not more restrictive than Original Medicare's. Documentation of diagnosis, previous therapies, and clinical rationale is paramount.

Navigating Beovu Denials and Appeals with Humana

Common reasons for Beovu prior authorization denials from Humana may include insufficient documentation of medical necessity, lack of compliance with step therapy protocols, or non-adherence to NCD/LCD guidelines for Medicare Advantage. Denials are typically communicated via X12 277/835 transactions or portal status updates. Humana's appeal pathway for Medicare Advantage follows the CMS-mandated 5-level structure, while commercial appeals follow distinct processes detailed in provider manuals.

Humana's Turnaround Times and CMS-0057-F Compliance

Humana's Medicare Advantage lines are impacted payers under CMS-0057-F, which mandates tighter prior authorization decision timeframes. While statutory timeframes for standard pre-service organization determinations are 14 calendar days (72 hours for expedited), CMS-0057-F will further shorten these to 7 calendar days for standard PA and 72 hours for expedited decisions for certain categories, with phased compliance through 2027.

Automating Humana Beovu Prior Authorizations with Klivira

Klivira integrates with EMRs and payer portals, including those used by Humana, to automate the prior authorization workflow for high-volume drugs like Beovu. Our platform streamlines submission, monitors status, and helps manage documentation requirements, aiming to reduce administrative burden and accelerate approval times for critical wet AMD treatments.

Frequently asked questions

Which Humana portal should I use to submit a prior authorization for Beovu?

For Beovu, which is typically administered under the medical benefit, prior authorization requests for Humana members are primarily submitted through Availity Essentials. This portal allows for PA initiation, eligibility verification, and secure document uploads. X12 278 transactions are also accepted via clearinghouses for medical benefit PA.

Does Humana require step therapy for Beovu for wet AMD?

Humana's medical policies, accessible on its provider site, specify utilization management criteria including potential step therapy requirements for anti-VEGF agents like Beovu. For Medicare Advantage members, these criteria must align with CMS NCDs and LCDs. Always consult the most current policy for specific requirements and discuss with your compliance team.

How can I appeal a denied Beovu prior authorization from Humana?

For Medicare Advantage members, denied Beovu prior authorizations follow the CMS-mandated 5-level appeal process, starting with a reconsideration request. For commercial plans, Humana's provider manual outlines the specific appeal pathways, which typically include peer-to-peer reviews and expedited appeal options.

What are the typical turnaround times for Beovu prior authorizations with Humana?

For Medicare Advantage, standard pre-service organization determinations have a statutory timeframe of 14 calendar days, with expedited decisions within 72 hours. Under CMS-0057-F, Humana's Medicare Advantage lines will be subject to tighter PA decision timeframes, reducing standard decisions to 7 calendar days, with phased compliance through 2027.

Is Beovu considered a medical benefit or pharmacy benefit drug by Humana?

Beovu is an intravitreal injection for wet AMD, administered in a clinical setting. Therefore, it typically falls under Humana's medical benefit. While CenterWell Specialty Pharmacy handles specialty drugs under the pharmacy benefit, Beovu's administration method places it under medical prior authorization.

Related coverage

Other beovu prior authorization by payer

Other beovu prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo